Clinical trial
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's…
NCT00211276 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00211276 |
|---|---|
| Title | A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma |
| Official title | A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non-Hodgkins Lymphoma. |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, B-Cell |
| Intervention type | Drug |
| Interventions | ONTAK (denileukin diftitox) |
| Enrollment | 50 |
| Start date | Mar 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 14, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: